Abstract 46P
Background
MicroRNAs (miRNAs), small non-coding RNAs that influence gene expression, have shown promising potential as biomarkers for cancer detection due to their stability and detectability in bodily fluids. Specifically, microRNA-1246 (miR-1246) has been preliminarily suggested to be effective in early-stage breast cancer detection, warranting an exhaustive analysis to verify its reliability and applicability as a non-invasive diagnostic indicator. The study aims to determine the accuracy of miR-1246 as a biomarker for the early detection of breast cancer.
Methods
A comprehensive search of databases, including PubMed, Embase, and the Cochrane Library, was conducted for studies published up to May 2023. Inclusion criteria were studies exploring the diagnostic efficacy of miR-1246 in early-stage breast cancer detection, with healthy individuals serving as a control group. Statistical analyses were performed using R software (version 4.0.3) with the mada package, which facilitated the pooling of sensitivity, specificity, false-positive rate estimates, diagnostic odds ratio, and both positive and negative Likelihood Ratios (LR), each with a 95% Confidence Interval (CI).
Results
Our meta-analysis consisted of 5 studies involving 3041 participants, with 1489 patients diagnosed with breast cancer and 1552 healthy controls. miR-1246 showed considerable diagnostic potential for early-stage breast cancer detection, exhibiting a sensitivity of 87.1% (95% CI: 76.9-93.2%, I2=78.6%) and a specificity of 89.4% (95% CI: 81.6-94.1%, I2=82%). The diagnostic odds ratio (DOR) was 57.05 (95% CI: 21.91-148.54), and the false-positive rate was 10.6% (95% CI: 5.9-18.4%). Additionally, Likelihood Ratios (LR) indicated a positive LR of 8.23 (95% CI: 4.59-14.75) and a negative LR of 0.14 (95% CI: 0.08-0.27).
Conclusions
The study highlights the promising potential of miR-1246 as a non-invasive biomarker for early breast cancer detection, though the observed heterogeneity across studies underscores the need for further comprehensive research. If validated with further studies, the integration of miR-1246 into existing diagnostic methods could significantly enhance early detection and improve patient prognosis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract